News Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

2012201120102009200820072003

2019 Archives

Nov 13, 2019

Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Jefferies 2019 Healthcare Conference in London on Wednesday, November 20, 2019 at 4:00 p.m. Greenwich...

More
Nov 10, 2019

Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment...

More
Nov 9, 2019
New Data Presented for Previously Untreated Metastatic Melanoma Patients in PIVOT-02 Study of Bempegaldesleukin with Nivolumab

Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy...

More
Nov 6, 2019

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2019. Cash and investments in marketable securities at September 30, 2019 were...

More
Nov 1, 2019

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at...

More
Oct 30, 2019

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of U.S.-based financial markets. Howard Robin,...

More
Oct 16, 2019

Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for...

More
Oct 7, 2019

Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and...

More
Oct 2, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer...

More
Oct 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team: Jonathan Zalevsky, Ph.D. has been promoted to Chief Research & Development Officer Gil M....

More
Sep 26, 2019
Analyst conference call with breast cancer specialist to be held at 2:30 p.m. Central European Summer Time (CEST)/8:30 a.m. Eastern Daylight Time (EDT) today

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin (bempeg, NKTR-214) in combination with nivolumab in patients with advanced or...

More
Sep 23, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02 study will be presented...

More
Aug 8, 2019
Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 (bempegaldesleukin) Program

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion...

More
Aug 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for...

More
Jul 30, 2019

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of U.S.-based financial markets. Howard Robin, President...

More
Jun 13, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in...

More
Jun 11, 2019

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00...

More
Jun 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting in Chicago,...

More
May 23, 2019
Key Assets will Include NKTR-181, a Novel, First-in-Class, Investigational Opioid

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch...

More
May 15, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from...

More
May 8, 2019

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019. Cash and investments in marketable securities at March 31, 2019 were...

More
May 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019, after the close of U.S.-based financial markets. Howard Robin,...

More
Apr 2, 2019

Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist,...

More
Apr 1, 2019

Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin...

More
Mar 6, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference...

More
 

 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide